Zoledronic acid in myeloma: MRC Myeloma IX

The Lancet

Volumn 376, Issue 9757, 2010, Pages 1965-1966

  Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CLODRONIC ACID; DEXAMETHASONE; LENALIDOMIDE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE DISEASE; CANCER SURVIVAL; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; HUMAN; LOW DRUG DOSE; MYELOMA; NOTE; PRIORITY JOURNAL;

EID: 78650172101     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)62178-2     Document Type: Letter

References (13)

1. RA Kyle, MA Gertz, TE Witzig Review of 1,027 patients with newly diagnosed multiple myeloma Mayo Clin Proc 78 2003 21 33
2. EV McCloskey, JA Dunn, JA Kanis, IC MacLennan, MT Drayson Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma Br J Haematol 113 2001 1035 1043
3. JR Berenson, A Lichtenstein, L Porter Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group J Clin Oncol 16 1998 593 602
4. LS Rosen, D Gordon, M Kaminski Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase II, double blind, comparative trial Cancer J 7 2001 377 387
5. RA Kyle, GC Yee, MR Somerfield American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma J Clin Oncol 25 2007 2464 2472
6. E Terpos, O Sezer, PI Croucher The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network Ann Oncol 20 2009 1303 1317
7. MQ Lacy, A Dispenzieri, MA Gertz Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma Mayo Clin Proc 81 2006 1047 1053
8. GJ Morgan, FE Davies, WM Gregory on behalf of the NCRI Haematological Oncology Clinical Study Group First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial Lancet 2010 10.1016/S0140-6736(10)62051-X published online Dec 4.
9. MT Drake, BL Clarke, S Khosla Bisphosphonates: mechanism of action and role in clinical practice Mayo Clin Proc 83 2008 1032 1045
10. KL Kavanagh, K Guo, JE Dunford The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs Proc Natl Acad Sci USA 103 2006 7829 7834
11. A Guenther, S Gordon, M Tiemann The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation Int J Cancer 126 2010 239 246
12. SV Rajkumar, S Jacobus, NS Callander for the Eastern Cooperative Oncology Group Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol 11 2010 29 37
13. M Attal, J-L Harousseau, S Leyvraz for the Inter-Groupe Francophone du Myélome Maintenance therapy with thalidomide improves survival in patients with multiple myeloma Blood 108 2006 3289 3294